Metabolism Disorder TRIZ Cases

D-amino acid substitution reduces side effects while improving insulin sensitivity without increasing pancreatic beta cell secretion.

Formula I compounds inhibit choline conversion to trimethylamine, reducing cardiovascular disease risk linked to elevated levels.

METRNL protein addresses the lack of effective hypoglycemic agents by lowering blood glucose and triglyceride levels via adipose-specific overexpression.

Peptide co-agonists attach fatty acid groups to extend half-life and enable once-weekly dosing.

A PCSK9 vaccine combines distinct epitope fragments to trigger antibody production that increases liver LDL receptor density.

Polymer matrices stabilize amorphous dapagliflozin dispersions, resolving hygroscopicity issues while maintaining rapid dissolution profiles.

Combines SGLT-2 inhibitor and angiotensin receptor blocker in a single pharmaceutical composition.

Primula Delta6-desaturase enzymes catalyze double bond formation to increase stearidonic acid levels in transgenic plant oils.

IL-2 selective agonist fused to IgG Fc via peptide linker activates regulatory T cells with prolonged half-life.

A segmented glucan dialysate composition achieves higher osmolality to drive fluid removal during peritoneal dialysis sessions.

A soybean isoflavone and L-carnitine mixture promotes lipolysis to reduce body fat.

Aromatic-cationic peptide penetrates cell membranes to reduce oxidative stress and recover mitochondrial redox status.

Bile acid sequestrants bind elevated bile acids to eliminate liver and intestinal toxicity caused by FGFR4 inhibition therapies.

Monoclonal antibodies bind pathologically aggregated hIAPP, clearing toxic species to preserve beta-cell mass and function.

Allogenic fecal matter transplantation from donors with BMI at least 30 kg/m2 and HOMA-IR below 2.5 mg/dL improves progression-free survival in cancer patients.

A multi-herbal composition lowers blood glucose levels through synergistic ingredient ratios.

Cationic surfactants stabilize glucagon in aqueous solution, preventing aggregation and deamidation during storage.

Salsolinol activates AMPK to reduce blood glucose levels, addressing the lack of effective activators in current diabetes treatments.

Unacylated ghrelin mobilizes circulating angiogenic cells, reducing oxidative stress damage and improving vascular remodeling in diabetic patients.

Nesfatin-1 and Pladin peptides regulate blood glucose levels through metabolic pathways.

Carrageenan protects amorphous fluvastatin from acidic degradation and oxidation, enabling zero-order dissolution without burst release.

Isolated mitochondria enhance cellular lipid and cholesterol metabolism to treat obesity without complex pharmaceutical side effects.

Transplastomic plants produce and protect Exendin 4 within chloroplasts, preventing proteolytic degradation during oral administration.

Exenatide administration reduces bowel frequency and esophageal contraction amplitudes in short bowel syndrome patients.

A Cistanche tubulosa extract and ubiquinone composition increases endurance performance and muscle strength.

Combining lipophilic and hydrophilic statins reduces side effects while achieving greater LDL cholesterol reduction than single-agent therapy.

A hybrid polyplex system conjugates biotinylated scFv antibodies to maltose and cyclodextrin-modified dendrimers for selective cellular uptake.

Determines the parental origin of specific genetic variants to resolve the trade-off between analysis speed and prediction accuracy in diabetes risk assessment.

Insulin degludec reduces severe hypoglycaemia risk while maintaining reliable glycaemic control in high-risk populations.

Covalent Vitamin B12-insulin conjugate leverages natural uptake mechanisms to transport therapeutic peptides across the intestinal lining.

Segmented water-ethanol extraction and pH-adjusted resin adsorption increase active component content while reducing impurities in the formulation.

Replacing reactive excipients with compatible alternatives prevents chemical degradation of the amino group in low-dosage solid forms.

PEGylated oxyntomodulin derivatives resist dipeptidyl peptidase IV cleavage, extending half-life for metabolic disorder treatment.

A scanning apparatus uses a detection module and switch unit to route voltage signals from USB or external sources.

A chemically crosslinked alginic acid hydrogel encapsulates insulin-secreting cells using a Huisgen reaction to form a stable semipermeable barrier.

Migalastat hydrochloride stabilizes mutant alpha-Gal A enzyme structure to enhance lysosomal trafficking, reducing GL-3 accumulation in kidney cells.

Sulforaphane compositions modulate blood lactate levels, resolving the trade-off between ketone-induced acidosis and exercise adaptation.

Optimized pH and zinc concentration in insulin glargine U300 formulations enhance bioavailability.

Segmented polymeric carriers maintain solubility while binding peptides, preventing aggregation in concentrated formulations.

Chorionic gonadotropin carboxy terminal peptide conjugation extends oxyntomodulin serum half-life.

Extraction of pure eicosapentaenoic acid from fish oil eliminates allergenic proteins and reduces eructation incidence in fish-allergic patients.

Para nitro amino derivatives lower methane emissions by at least 10% while improving feed conversion and weight gain.

A plant extract composition containing oleanolic acid and berberine enhances bioavailability of active ingredients.

HSP27 proteins decrease PCSK9 expression to lower LDL cholesterol without statin-induced liver toxicity.

LRP receptor mediates TGF-β growth inhibition to resolve cancer cell resistance through IRS phosphorylation.

Integrating oral and gut microbiota analysis via metagenomic sequencing overcomes limited biomarker availability for early rheumatoid arthritis detection.

Pegylated exendin-4 derivatives act as GLP-1 receptor antagonists to treat hyperinsulinemic hypoglycemia.

Weekly 200 unit parathyroid hormone administration improves bone density while avoiding hypercalcemia risks associated with daily dosing.

Long-chain α,ω-dicarboxylic acid compounds sensitize tissues to insulin, reducing systemic resistance and standard dosing requirements in type 1 diabetes.